DENVER, May 3, 2012 /PRNewswire/ -- MusclePharm
Corporation (OTCBB: MSLP), a nutritional supplement company
focusing on all categories of an active lifestyle, today said that,
in light of yesterday's FDA ban on the substance DMAA, which is not
used in MusclePharm products, it expects to capture a wider market
share, particularly for the company's pre-workout supplement
Assault™, which is the only pre-workout product on the
market that is certified by both NSF International and Informed
Choice as free of banned substances. Yesterday, the United
States Food and Drug Administration (FDA) imposed a ban on the
supplement 1,3-Dimethylamine (DMAA), an ingredient used by many
supplement companies MusclePharm competes with, citing its
potentially fatal side effects.
"MusclePharm is committed to providing products that are safe,
effective and free of any banned substances," said Dr. Roscoe Moore, former U.S. Assistant Surgeon
General and Chief Scientific Director for MusclePharm. "We
have a top-notch team of physicians and other medical experts, we
well as a highly competent Scientific Advisory Board, that oversee
the creation and production of all of our products.
MusclePharm made an intentional decision to stay away from DMMA
when it formulated the pre-workout product, Assault, for the same
reasons the FDA has now banned the ingredient. We believe
this differentiates MusclePharm from its competitors and ensures
our products are backed by real science."
The company's product, Assault, has become the No. 1-selling
pre-workout supplement on Bodybuilding.com, the world's largest
online nutritional retailer. Assault contains large amounts
of Branch-Chain Amino Acids (BCAAs) and Beta Alanine and Creatine,
which have been proven to naturally increase performance in
athletes.
"Developed at the state-of-the-art MusclePharm Sports Science
Center, Assault is one of the most researched and rigorously tested
pre-workout supplements on the market," said MusclePharm Chief
Executive Officer Brad Pyatt.
"By offering high quality, scientifically backed products,
MusclePharm is a leading supplement company that is able to back up
its claims with a wide array of clinical studies and scientific
research. We believe this is why so many athletes,
professional baseball organizations and the UFC partner with us,
and why we believe MusclePharm is the future in the sports
nutrition industry."
A recently-released peer-reviewed journal, Nutrition and
Metabolism, published a scientific paper showing positive
results on the Phase 1 clinical trial of the company's pre-workout
supplement, Assault. Conducted at the United States Sports Academy (USSA) (www.ussa.edu),
the study suggests that ingesting Assault 20 minutes prior to
exercise can improve agility, quickness and lower-body muscular
strength in both strength and/or endurance-trained young adult
males. Moreover, the study showed that Assault can improve
energy, focus and alertness, and delay fatigue.
"Our findings suggest that Assault can provide athletes with an
overall better workout experience by prolonging exercise
performance, reducing fatigue and increasing energy-levels," said
Jordan R. Moon, Ph.D., lead
researcher of the clinical trial and USSA's Head of the Department
of Sports Fitness and Health. "The athlete-subjects who
consumed Assault lifted more weight, were faster in reaction tests
and were motivated to continue to exercise."
The abstract is entitled "Ingesting a pre-workout supplement
containing caffeine, B-vitamins, amino acids, creatine, and
beta-alanine before exercise delays fatigue while improving
reaction time and muscular endurance" and can be downloaded at
www.nutritionandmetabolism.com/content/9/1/28/abstract.
ABOUT MUSCLEPHARM CORPORATION
MusclePharm is a healthy life-style company that develops and
manufactures a full line of NSF International and Informed Choice
approved nutritional supplements that are free of banned
substances. Based on years of research at the MusclePharm Sports
Science Center, the products are created through an advanced
six-stage research protocol involving the expertise of top
nutritional scientists and field tested by more than one hundred
elite professional athletes from various professional sports
leagues including the National Football League, Mixed Martial Arts
and Major League Baseball. The company's products address all
categories of an active lifestyle, including muscle building,
weight loss and maintaining general fitness through a daily
nutritional supplement regimen. MusclePharm is sold in more than
120 countries and available in over 10,000 U.S. retail outlets,
including Dick's Sporting Goods, GNC, Vitamin Shoppe, Vitamin World
and Walmart. MusclePharm products also are sold through more than
100 online stores, including bodybuilding.com, Amazon.com and
Vitacost.com. For more information, please visit
www.musclepharm.com.
FORWARD LOOKING STATEMENTS
The information contained herein includes forward-looking
statements. These statements, including, but not limited to,
capturing a wider market share for its products based on the ban of
the substance DMAA, relate to future events or to future financial
performance, and involve known and unknown risks, uncertainties and
other factors that may cause actual results, levels of activity,
performance, or achievements to be materially different from any
future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements.
Undue reliance should not be placed on forward-looking
statements, since they involve known and unknown risks,
uncertainties and other factors which are, in some cases, beyond
the company's control and which could, and likely will, materially
affect actual results, levels of activity, performance or
achievements. Any forward-looking statement reflects the company's
current views with respect to future events and is subject to these
and other risks, uncertainties and assumptions relating to
operations, results of operations, growth strategy and liquidity.
MusclePharm assumes no obligation to publicly update or revise
these forward-looking statements for any reason, or to update the
reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new
information becomes available in the future.
For more information, contact:
PondelWilkinson Inc.
Roger Pondel/Robert Jaffe
310-279-5980
SOURCE MusclePharm Corporation